Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Leist, Thomas P, Prof, Comi, Giancarlo, Prof, Cree, Bruce A C, Prof, Coyle, Patricia K, Prof, Freedman, Mark S, Prof, Hartung, Hans-Peter, Prof, Vermersch, Patrick, Prof, Casset-Semanaz, Florence, MS, Scaramozza, Matthew, MA
Published in Lancet neurology (01.03.2014)
Published in Lancet neurology (01.03.2014)
Get full text
Journal Article